Afya (AFYA) Projected to Post Quarterly Earnings on Thursday

Afya (NASDAQ:AFYA) is projected to release its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect Afya to post earnings of $0.36 per share and revenue of $174.7420 million for the quarter. Interested persons may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, March 12, 2026 at 5:00 PM ET.

Afya Stock Up 1.1%

Shares of NASDAQ AFYA opened at $14.01 on Tuesday. The stock has a fifty day moving average price of $14.51 and a 200 day moving average price of $14.80. The company has a current ratio of 0.98, a quick ratio of 0.98 and a debt-to-equity ratio of 0.21. Afya has a 12-month low of $13.00 and a 12-month high of $19.90. The company has a market cap of $1.31 billion, a P/E ratio of 10.08, a P/E/G ratio of 0.67 and a beta of 0.52.

Institutional Trading of Afya

A number of hedge funds and other institutional investors have recently modified their holdings of AFYA. Susquehanna International Group LLP acquired a new position in shares of Afya in the third quarter worth about $419,000. Engineers Gate Manager LP acquired a new stake in Afya during the 2nd quarter valued at approximately $363,000. Lazard Asset Management LLC grew its stake in Afya by 166.6% during the 2nd quarter. Lazard Asset Management LLC now owns 18,463 shares of the company’s stock valued at $329,000 after purchasing an additional 11,537 shares in the last quarter. Marshall Wace LLP purchased a new stake in Afya during the 2nd quarter worth approximately $249,000. Finally, Sei Investments Co. purchased a new stake in Afya during the 3rd quarter worth approximately $244,000. 88.02% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on AFYA shares. Wall Street Zen downgraded Afya from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 31st. Bank of America downgraded Afya from a “buy” rating to a “neutral” rating and dropped their target price for the company from $22.00 to $17.00 in a report on Tuesday, February 24th. UBS Group reissued a “neutral” rating and set a $16.00 price target (down from $18.00) on shares of Afya in a research report on Friday, January 16th. Sanford C. Bernstein upgraded Afya to a “market perform” rating in a report on Friday, January 16th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Afya in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $17.30.

About Afya

Afya Ltd. operates as a leading provider of medical education and training services in Brazil. The company offers a comprehensive suite of educational programs that span undergraduate medical degrees, residency exam preparation, continuing medical education (CME) and digital learning platforms. Through a network of partner institutions and its own campus operations, Afya supports students at every stage of the medical training continuum, from enrollment in medical schools to ongoing professional development for practicing physicians.

At the core of Afya’s offerings is its undergraduate medical program, delivered through a combination of in-person courses at affiliated campuses and fully digital curricula.